GlassScriptPhysician profile
David T Wortham
NPI 1437101771
$9,881.64
in general payments reported to CMS, 2019-2025
46 companies · $1,893 in 2025
The $1,893 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $934 · 2021: $1,191 · 2022: $1,581 · 2023: $1,399 · 2024: $1,625 · 2025: $1,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,872 · Education: $44.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,872.16 |
| Education | $44.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,366.91 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Pfizer INC. | $963.36 | 2019-2025 | |
| Janssen Biotech, INC. | $807.75 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $478.05 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $471.72 | 2019-2025 | Dificid, Keytruda, Zinplava |
| Gilead Sciences, INC. | $467.05 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.08 | 2019-2023 | Xifaxan |
| Daiichi Sankyo INC. | $349.67 | 2019-2025 | Injectafer, Enhertu |
| Lilly USA, LLC | $309.43 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $257.42 | 2019-2024 | Entyvio |
| Nestle Healthcare Nutrition INC. | $241.69 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $220.69 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $220.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $218.13 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $165.92 | 2019-2025 | Ocaliva |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $163.98 | 2024-2025 | Iqirvo, Bylvay |
| Intra-Sana Laboratories | $143.80 | 2021-2022 | |
| Celltrion USA INC. | $143.26 | 2024-2025 | Zymfentra, Vegzelma |
| Ferring Pharmaceuticals INC. | $117.83 | 2022-2023 | Rebyota |
| Organon LLC | $117.77 | 2024-2025 | Renflexis, Hadlima |
| Boston Scientific Corporation | $101.44 | 2021-2025 | Acquire, Habib Endohpb |
| Covidien LP | $87.06 | 2019 | |
| Shionogi INC | $82.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.49 | 2023-2024 | Cyltezo |
| Genzyme Corporation | $80.10 | 2024-2025 | |
| Ucb, INC. | $77.61 | 2019 | |
| Amgen INC. | $74.13 | 2020-2023 | Avsola, Amjevita |
| Braintree Laboratories, INC. | $71.77 | 2019-2025 | Sutab, Suflave |
| Endo Pharmaceuticals INC. | $71.71 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $66.31 | 2020 | |
| Aimmune Therapeutics, INC. | $58.40 | 2024-2025 | Zenpep, Vowst |
| E.R. Squibb & Sons, L.L.C. | $57.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $55.66 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $53.00 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $39.33 | 2025 | Wegovy |
| Redhill Biopharma INC. | $38.67 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $24.81 | 2024 | Terlivaz |
| Ethicon US, LLC | $23.98 | 2022 | |
| Alfasigma USA, INC. | $23.64 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $22.66 | 2024 | Andexxa |
| Jazz Pharmaceuticals INC. | $20.56 | 2023 | |
| Shire North American Group INC | $18.96 | 2019 | |
| Mylan Institutional INC. | $16.57 | 2023 | Hulio |
| Olympus America INC. | $16.15 | 2023 | Endoclot Phs |
| Allergan, INC. | $14.50 | 2019 | |
| Pharmacosmos Therapeutics INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wortham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.